Myriad Genetics shows strong commitment, support in the fight against colorectal cancer


Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic testing during National Colorectal Cancer Awareness Month. As the third most commonly diagnosed cancer in both men and women in the United States, colon cancer kills one person every 10 minutes.



from Biotech News